DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Insulin Like Growth Factor 2 (Somatomedin-A or IGF-2) - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Insulin Like Growth Factor 2, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Like Growth Factor 2 and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Insulin Like Growth Factor 2 Overview
- Therapeutics Development
- Pipeline Products for Insulin Like Growth Factor 2 - Overview
- Pipeline Products for Insulin Like Growth Factor 2 - Comparative Analysis
- Insulin Like Growth Factor 2 - Therapeutics under Development by Companies
- Insulin Like Growth Factor 2 - Therapeutics under Investigation by Universities/Institutes
- Insulin Like Growth Factor 2 Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Insulin Like Growth Factor 2 - Products under Development by Companies
- Insulin Like Growth Factor 2 - Products under Investigation by Universities/Institutes
- Insulin Like Growth Factor 2 - Companies Involved in Therapeutics Development
- Boehringer Ingelheim GmbH
- MedImmune, LLC
For more information about this report visit http://www.researchandmarkets.com/research/rvk8ql/insulin_like
Related Topics: Immune Disorders Drugs